• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by GH Research PLC

    2/27/25 8:34:59 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GHRS alert in real time by email
    S-8 1 ny20044079x2_s8.htm S-8

    As filed with the Securities and Exchange Commission on February 27, 2025
    Registration No. 333-


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549



    FORM S-8
    REGISTRATION STATEMENT
    UNDER THE SECURITIES ACT OF 1933
     

     
    GH Research PLC
    (Exact Name of Registrant as specified in its charter)

    Ireland
    N/A
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)

     
    GH Research PLC
    Joshua Dawson House
    Dawson Street
    Dublin 2
    D02 RY95
    Ireland
    Tel: +353 1 437 8334
     
    (Address, including zip code, and telephone number, including area code, of Principal Executive Offices)



    GH Research PLC Share Option Plan
     
    (Full title of the plan)
     



    Cogency Global Inc.
    122 East 42nd Street, 18th Floor
    New York, NY 10168
    Tel: (800) 221-0102
    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     
    Copies to:
     
     
    Adam Kaminsky
    Davis Polk & Wardwell LLP
    450 Lexington Avenue
    New York, NY 10017
    (212) 450-4000
     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ☐
    Accelerated filer ☒
    Non-accelerated filer ☐ (Do not check if a smaller reporting company)
    Smaller reporting company ☐
     
    Emerging Growth Company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    PART I

    REGISTRATION OF ADDITIONAL SECURITIES PURSUANT TO GENERAL INSTRUCTION

    Pursuant to General Instruction E to Form S-8, GH Research PLC (the “Registrant”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) with the U.S. Securities and Exchange Commission (the “Commission”) to register 999,970 additional ordinary shares, nominal value $0.025 per share, for issuance under the GH Research PLC Share Option Plan, as amended November 24, 2024. This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statement on Form S-8 filed with the Commission on March 9, 2023 (Registration No. 333-270422).

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.  Incorporation of Documents by Reference.

    The following documents are incorporated herein by reference:

    (a) The annual report on Form 20-F of GH Research PLC (the “Registrant”) for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025; and

    (b) The description of the Registrant’s share capital which is contained in the Registrant’s Registration Statement on Form 8-A (Registration No. 001-40530), dated June 22, 2021, including any amendments or supplements thereto.

    In addition, all documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, including any Reports of Foreign Private Issuers on Form 6-K submitted during such period (or portion thereof) that is identified in such form as being incorporated by reference into this Registration Statement, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents. The Registrant is not incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed “filed” with the Commission.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 8.  Exhibits.

    Exhibit
    Number
       
    4
     
    Constitution of GH Research PLC (incorporated herein by reference to Exhibit 1.1 of the Registrant’s Annual Report on Form 20-F for the fiscal year ended December 31, 2022, filed with the Commission on March 9, 2023).

    5
     
    Opinion of A&L Goodbody LLP (filed herewith)

    23.1
     
    Consent of A&L Goodbody LLP (included in Exhibit 5)

    23.2
     
    Consent of PricewaterhouseCoopers an independent registered public accounting firm (filed herewith)

    24
     
    Powers of Attorney (included in the signature pages hereto)

    99
     
    GH Research PLC Share Option Plan, as amended November 24, 2024 (incorporated by reference to Exhibit 4.1 of the Registrant’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025)

    107
     
    Filing Fee Table


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Registration Statement and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dublin, Ireland, on this 27th day of February, 2025.

     
    GH Research PLC

     
    By:
    /s/ Julie Ryan
     
    Name:
    Julie Ryan
     
    Title:
    Vice President, Finance
         



    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Velichka Valcheva and Julie Ryan, either of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and any and all additional registration statements pursuant to Rule 462(b) of the Securities Act and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agent full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature
     
    Title
    Date
     
    /s/ Velichka Valcheva 
     
    Chief Executive Officer
    February 27, 2025
    Velichka Valcheva
     
    (Principal Executive Officer)
     
     
    /s/ Julie Ryan 
     
    Vice President, Finance
    February 27, 2025
    Julie Ryan
     
    (Principal Financial Officer and Principal Accounting Officer)
     
     
    /s/ Florian Schönharting 
     
    Director
    February 27, 2025
    Florian Schönharting
         
     
    /s/ Michael Forer 
     
    Director
    February 27, 2025
    Michael Forer
         
     
    /s/ Dermot Hanley 
     
    Director
    February 27, 2025
    Dermot Hanley
         
     
    /s/ Duncan Moore 
     
    Director
    February 27, 2025
    Duncan Moore
         



    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

    Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of America, has signed this registration statement thereto in New York, NY on February 27, 2025.


    Authorized U.S. Representative--Cogency Global Inc.
         
     
    By:  
    /s/ Colleen A. De Vries
       
    Name: Colleen A. De Vries
     
    Title: Senior Vice-President on behalf of
     
    Cogency Global Inc.



    Get the next $GHRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GHRS

    DatePrice TargetRatingAnalyst
    10/13/2025$19.00Buy
    Needham
    6/4/2025$25.00Overweight
    Cantor Fitzgerald
    3/13/2025$32.00Buy
    Guggenheim
    3/7/2025$31.00Outperform
    RBC Capital Mkts
    2/13/2025$14.00Overweight
    Cantor Fitzgerald
    8/16/2022$45.00Buy
    H.C. Wainwright
    6/16/2022$66.00Buy
    ROTH Capital
    7/20/2021Buy
    Stifel
    More analyst ratings

    $GHRS
    SEC Filings

    View All

    SEC Form 6-K filed by GH Research PLC

    6-K - GH Research PLC (0001855129) (Filer)

    1/22/26 7:02:30 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by GH Research PLC

    6-K - GH Research PLC (0001855129) (Filer)

    1/15/26 7:00:51 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by GH Research PLC

    6-K - GH Research PLC (0001855129) (Filer)

    1/13/26 7:15:47 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GHRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026

    GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program replicating Phase 2b designPhase 3 initiation targeted for 2026 DUBLIN, Jan. 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug Application (IND) for GH001. This clearance enables U.S. subject enrollment and progresses the company toward alignment of its development ac

    1/5/26 7:00:00 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GH Research to Announce IND Status for GH001

    DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported that it will provide an update on the status of its Investigational New Drug Application (IND) for GH001 with the U.S. Food and Drug Administration (FDA) and its global pivotal Phase 3 program in treatment-resistant depression (TRD) on Monday, January 5, 2026, at 7.00 a.m. EST. About GH Research PLC GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in

    1/2/26 4:01:00 PM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress

    DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Novel Therapies Symposium Presentation at the 38th Annual European College of Neuropsychopharmacology Congress (ECNP) in Amsterdam, the Netherlands from October 11 – 14, where Professor Wiesław J. Cubała, MD, PhD, Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, will present long-term clinical data on the safety and efficacy from the open label extension (OLE) of a randomized, double-blind, placebo-controlle

    10/9/25 7:00:07 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GHRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on GH Research PLC with a new price target

    Needham initiated coverage of GH Research PLC with a rating of Buy and set a new price target of $19.00

    10/13/25 8:53:27 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on GH Research PLC with a new price target

    Cantor Fitzgerald resumed coverage of GH Research PLC with a rating of Overweight and set a new price target of $25.00

    6/4/25 8:19:53 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on GH Research PLC with a new price target

    Guggenheim initiated coverage of GH Research PLC with a rating of Buy and set a new price target of $32.00

    3/13/25 7:38:21 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GHRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GH Research PLC

    SC 13G/A - GH Research PLC (0001855129) (Subject)

    11/14/24 5:46:11 PM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by GH Research PLC

    SC 13G/A - GH Research PLC (0001855129) (Subject)

    11/14/24 9:05:43 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by GH Research PLC

    SC 13G - GH Research PLC (0001855129) (Subject)

    2/16/24 4:57:41 PM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GHRS
    Leadership Updates

    Live Leadership Updates

    View All

    GH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive Officer

    DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the promotion of Dr. Velichka "Villy" Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Terwey, co-founder of GH Research. Dr. Valcheva has more than 20 years of experience in various leadership roles in the pharmaceutical and biotech industries. Dr. Valcheva joined the company in August 2023 and has served as the Company's Chief Medical Officer since February 2024 having leadership responsibility, among other thin

    9/3/24 7:00:05 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

    DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates. Second Quarter 2023 Financial Highlights Cash position Cash, cash equivalents, other financial assets and marketable securities were $238.1 million as of June 30, 2023, compared to cash, cash equivalents and marketable securities of $251.7 million as of December 31, 2022. Cash equivalents and other financial assets comprise money market funds. Marketable securities comprise inv

    8/23/23 7:00:45 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GHRS
    Financials

    Live finance-specific insights

    View All

    GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

    Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients treated with GH001 achieved remission with a 57.5% remission rate on Day 8 compared with 0% in the placebo group (p<0.0001)All other secondary endpoints were met with clinically and statistically significant improvements on Day 8, compared with placeboDuring the double-blind part, GH001 was well tolerated and no serious adverse events (SAE) were reported. There was no evidence of treatment-emergent suicidal ideation or behavior. As of January 22, 2025, no SAEs have been reported throughout the open

    2/3/25 7:00:10 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

    DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD). To access the conference call, please register in advance here. A live webcast of the call will be available under "Events & Presentations" in the Investors section of GH Research PLC's website at ghres.com. About GH Research PLC GH

    1/31/25 4:01:35 PM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care